In NLRP3-mutant mice, the inhibition of ASK1 alleviated liver fibrosis and inflammation [121]; however, phase III trials of the ASK1 inhibitor selonsertib did not demonstrate benefits in patients with MASH or severe alcoholic hepatitis (AH) compared to standard treatment [65]. Here, MAP3K5 is linked to metabolic dysfunction-associated steatohepatitis.